
3 Brand-Name, Ultra-High-Yield Dividend Stocks Patient Investors Can Confidently Buy With $300 Right Now
With thousands of publicly traded companies and exchange-traded funds (ETFs) to choose from, Wall Street offers no shortage of ways for investors to grow their wealth. But among this vast sea of pathways to become richer is one of the most-successful strategies: buying and holding high-quality dividend stocks.
Companies that pay a regular dividend often share a few traits:
They're usually profitable on a recurring basis.
They're often capable of providing transparent long-term growth outlooks.
They've demonstrated to Wall Street they can successfully navigate their way through recessions.
More importantly, dividend stocks have a knack for outperforming. In The Power of Dividends: Past, Present, and Future, researchers at Hartford Funds, in collaboration with Ned Davis Research, found that dividend stocks averaged an annualized return of 9.17% from 1973 through 2023, and did so while being 6% less volatile than the broad-based S&P 500. Meanwhile, the non-payers delivered a more modest annualized return of 4.27% over the same half century, and were 18% more volatile than the benchmark S&P 500.
Ideally, investors want the highest yield possible with the least amount of risk. The issue is that risk and yield tend to correlate, which means a lot of vetting is necessary on the part of investors to avoid getting stuck in a yield trap.
The good news is there are three exceptionally well-known, ultra-high-yield dividend stocks -- sporting an average yield of 6.65% -- which can be bought with confidence right now by patient investors with $300.
Pfizer: 6.74% yield
The first brand-name stock that long-term income seekers can set and forget in their portfolios is pharmaceutical goliath Pfizer (NYSE: PFE), whose 6.74% yield is nearing an all-time high.
Although Pfizer's stock chart gives the perception that it's struggling, a deeper dive into the company's operating performance shows it's been a victim of its own success. After generating in excess of $56 billion in sales from its COVID-19 therapies in 2022, Pfizer's combined COVID-19 drug sales fell to a little over $11 billion in 2024.
But taking a wider-lens approach completely changes the perspective of this data. Although COVID-19 sales declined by around $45 billion over the last two years, any revenue generated from Pfizer's COVID-19 vaccine (Comirnaty) and oral therapy (Paxlovid) compares quite favorably with the $0 it was generating from this segment four years ago. Between 2020 and 2024, Pfizer's net sales soared 52% to $63.6 billion. That's not a struggling business.
Something else exciting is Pfizer's $43 billion acquisition of cancer-drug developer Seagen in December 2023. This deal vastly expands Pfizer's oncology pipeline and provides an immediate boost to its sales. It'll also result in significant cost savings, which are reflected in its 2025 profit forecast.
Pfizer benefits from healthcare being a highly defensive industry, as well. Since we don't get to choose when we become ill or what ailment(s) we develop, the company's operating cash flow tends to be predictable and consistent. This makes its forward price-to-earnings (P/E) ratio of 8 quite the bargain.
Verizon Communications: 6.69% yield
A second brand-name stock that can be confidently scooped up with $300 by opportunistic long-term investors is telecom stalwart Verizon Communications (NYSE: VZ). Verizon's nearly 6.7% yield is also approaching an all-time high.
If there's a knock against Verizon, it's that it's not an artificial intelligence (AI) stock. Investors are gravitating to high-growth, high-volatility tech stocks, and not mature businesses like Verizon that generate low-single-digit sales growth and highly predictable cash flow. But investor apathy toward this telecom giant can be income seekers' gain.
The beauty of wireless services and the internet is that both are viewed as basic necessities. During periods of economic turbulence, consumers are unlikely to cancel their access to the outside world. Wireless retail postpaid churn rate was only 1.12% during the fourth quarter, with average revenue per account climbing by 4.2% from the prior-year period. Consumers are sticking around, with the 5G revolution incenting a steady upgrade to wireless devices.
Though Verizon's growth heyday ended long ago, you wouldn't know it by homing in on the company's broadband operations. Total broadband connections grew to more than 12.3 million in 2024 (a 15% year-over-year increase), which has the potential to boost its operating cash flow. Best of all, broadband subscribers are more likely to bundle their services, which can improve customer loyalty and, ultimately, Verizon's operating margin.
The final thing to note about Verizon is that its financial flexibility is improving. Over the last two years, its total unsecured debt has declined by almost 10% to $117.9 billion. When coupled with a forward P/E ratio of around 8, Verizon stands out as an amazing deal.
Ford Motor Company: 6.51% yield
The third brand-name, ultra-high-yield dividend stock that patient investors can purchase with $300 right now is legacy automaker Ford Motor Company (NYSE: F). Excluding the COVID-19 crash in the first quarter of 2020, Ford's yield hasn't regularly parked above 6% since 2019.
Ford's yield topping 6% is a reflection of its stock touching a greater-than-four-year low this week. Steep losses from its electric vehicle (EV)-focused Model e segment in 2024, along with uncertainties that caused management to forecast a tough year in 2025 -- Ford's EBIT (earnings before interest and taxes) forecast of $7 billion to $8.5 billion for 2025 missed the mark -- led to a breakdown.
Despite the cyclical nature of legacy automakers, there are a handful of long-term catalysts investors can focus on. For example, Ford does have the luxury of adjusting its spending spigot to match consumer demand. Being mindful of tepid EV demand allows management to pare back spending and shift it to legacy segments that are generating healthy profits.
Ford's shareholders can also take solace in knowing the company is making strides to improve its production quality. While higher-than-anticipated warranty expenses have weighed on the company's profits in recent years, many of these issues can be traced to before Jim Farley became CEO in October 2020. In 2024, J.D. Power's "Initial Quality Study" put Ford in the top third of all brands examined in terms of fewest problems per 100 vehicles.
To round things out, Ford F-Series pickup has been the best-selling truck in the U.S. for the last 48 years, and the top-selling vehicle domestically (period!) over the last 43 years. While bigger isn't always better in the business world, trucks are statistically better than sedans at generating juicier vehicle margins for automakers. As long as Ford can maintain the popularity of its F-Series truck line, its forward P/E ratio of roughly 5.4 is a steal.
Should you invest $1,000 in Pfizer right now?
Before you buy stock in Pfizer, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
Learn more »
*Stock Advisor returns as of February 7, 2025
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
37 minutes ago
- Globe and Mail
Hormone Replacement Therapy Market Set to Grow at 6.48% CAGR Through 2030, Driven by Rising Demand
Hormone Replacement Therapy companies working in the market are Abbott, Novartis AG, Pfizer Inc., Merck KGaA, Bayer AG, Halozyme Therapeutics, Inc., Eli Lilly and Company, Viatris Inc., F. Hoffman-La Roche, Novo Nordisk A/S, Amgen Inc., Genentech, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Ascendis Pharma Endocrinology, Inc., Vista Pharma, Inc., Clarus Therapeutics, Inc., Gedeon Richter Plc, Endo International plc, and others. (Albany, USA) DelveInsight's ' Hormone Replacement Therapy Market Insights, Competitive Landscape, and Market Forecast–2030 ' report provides a comprehensive analysis of the global hormone replacement therapy (HRT) market, focusing on adoption trends, technological advancements, and market dynamics across key regions. The report examines market growth, offering historical and projected market sizes, revenue trends, and key factors driving the demand for HRT in managing hormonal imbalances. The report highlights the evolving landscape of hormone replacement therapies, exploring advancements in bioidentical hormones, transdermal delivery systems, and combination therapies that improve efficacy and patient compliance. It delves into how these innovations are enhancing treatment outcomes for conditions such as menopause, hypogonadism, thyroid disorders, and growth hormone deficiencies, providing safer and more personalized solutions. Additionally, the report evaluates the competitive landscape, profiling major players in the global HRT market while spotlighting emerging technologies and novel therapeutic approaches expected to drive future growth. It provides an in-depth review of ongoing clinical developments, regulatory progress, and recent product approvals, making it a vital resource for understanding the rapidly advancing field of hormone replacement therapy. Some of the key insights of the Hormone Replacement Therapy Market Report: The hormone replacement therapy market is projected to expand at a CAGR of 6.48% from 2024 to 2030. North America is estimated to hold a significant revenue share in the Hormone Replacement Therapy market. In September 2024, the FDA's Oncologic Drugs Advisory Committee (ODAC) recognized the favorable benefit-risk profile of PD-1 inhibitors, including TEVIMBRA® (tislelizumab-jsgr), for the first-line treatment of locally advanced or metastatic ESCC and G/GEJ cancers with PD-L1 >1%. In August 2024, the FDA approved Ascendis Pharma's Yorvipath (palopegteriparatide) as a parathyroid hormone replacement therapy for adults with hypoparathyroidism, with the first U.S. supply expected in early 2025. In June 2024, Mangoceuticals announced the development of proprietary Oral Dissolvable Tablet (ODT) formulations of Enclomiphene Citrate, Pregnenolone, and DHEA to restore hormonal balance and naturally boost testosterone levels in men. In May 2023, Astellas Pharma Inc. announced the U.S. Food and Drug Administration (FDA) approval for VEOZAH (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause. In January 2022, Pfizer, Inc. and OPKO Health, Inc. received approval from the Ministry of Health, Labor and Welfare, Japan, for the commercialization of NGENLA to treat growth hormone disorders. This product was the next-generation long-acting growth hormone injection, with a treatment frequency of a once-a-week dosage. Key players in the global Hormone Replacement Therapy market include Abbott, Novartis AG, Pfizer Inc., Merck KGaA, Bayer AG, Halozyme Therapeutics, Inc., Eli Lilly and Company, Viatris Inc., F. Hoffman-La Roche, Novo Nordisk A/S, Amgen Inc., Genentech, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Ascendis Pharma Endocrinology, Inc., Vista Pharma, Inc., Clarus Therapeutics, Inc., Gedeon Richter Plc, Endo International plc, and others. Hormone Replacement Therapy Overview Hormone Replacement Therapy (HRT) is a widely used treatment designed to replenish hormones that naturally decline due to aging or specific medical conditions. It is commonly prescribed for menopause-related symptoms in women, such as hot flashes, osteoporosis, and mood swings, as well as for hypogonadism and testosterone deficiency in men. Additionally, HRT plays a crucial role in managing conditions like hypothyroidism and growth hormone deficiencies. The therapy is available in various forms, including oral tablets, patches, injections, and topical gels, allowing personalized treatment approaches. Advancements in hormone formulations, including bioidentical and plant-derived hormones, have improved safety and efficacy, addressing concerns related to long-term use. Increasing awareness of hormonal imbalances and their impact on overall health is driving demand for HRT, making it a significant segment in the global healthcare market. Hormone Replacement Therapy Market Segment Analysis: The Hormone Replacement Therapy market report offers market segment analysis for the forecast period 2024-2030, segmented into: Hormone Replacement Therapy Market by Therapy (Estrogen Hormone Replacement, Growth Hormone Replacement, Thyroid Hormone Replacement, Testosterone Hormone Replacement, and Others) Hormone Replacement Therapy Market by Indication (Menopause, Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, and Others) Hormone Replacement Therapy Market by Route of Administration (Oral, Parenteral, and Transdermal) Hormone Replacement Therapy Market by Geography (North America, Europe, Asia-Pacific, and Rest of the World) Download the Hormone Replacement Therapy Market Analysis report for key market trends, innovations, and growth drivers. Hormone Replacement Therapy Market Dynamics One of the key factors driving the growth of the hormone replacement therapy market is the increasing awareness among women about managing menopausal symptoms. As women age, estrogen and progesterone levels decline significantly, leading to hormonal imbalances. In response, the pituitary gland increases follicle-stimulating hormone (FSH) production, causing symptoms such as hot flashes, excessive sweating, and palpitations. With a growing global population of women reaching menopause, the demand for hormone replacement therapy to manage these symptoms is expected to rise. Additionally, ongoing research and development efforts by key pharmaceutical companies are driving the discovery of novel treatments for hormonal imbalances. The increasing number of product approvals is further expanding the availability of hormone replacement therapies. Several companies are actively investing in the introduction of innovative therapies for conditions such as growth hormone deficiency and testosterone replacement, enhancing treatment options for both men and women. However, certain challenges may hinder market growth. The high costs associated with drug development, potential side effects linked to long-term hormone therapy use, and stringent regulatory approval processes remain significant barriers. Despite these challenges, the overall hormone replacement therapy market is expected to expand steadily, driven by advancements in treatment options and increasing patient awareness. North America Set to Lead the Growth of the Global Hormone Replacement Therapy Market North America is expected to dominate the hormone replacement therapy market, driven by the increasing demand for hormone replacement drugs among women due to the rising prevalence of menopausal-related issues. Additionally, the growing incidence of growth deficiencies, thyroid disorders, osteoporosis, and hypogonadism, along with active research and development efforts, is fueling market expansion in the region. The presence of key pharmaceutical companies, frequent product launches, and favorable reimbursement policies further support market growth. For instance, the increasing prevalence of thyroid-related conditions has led to a higher demand for hormone therapies, as these treatments play a crucial role in managing conditions like thyroid cancer and hormonal imbalances. Moreover, recent product relaunches and strategic collaborations among manufacturers are strengthening the market landscape. With these factors in play, North America is expected to maintain its leadership in the hormone replacement therapy market throughout the forecast period. Hormone Replacement Therapy Market Drivers Growing awareness of menopause-related health issues and a rising aging population are increasing the demand for HRT to manage symptoms like osteoporosis, cardiovascular risks, and hormonal imbalances. The development of safer, more effective hormone formulations, including bioidentical and plant-based options, has improved patient outcomes and increased adoption rates. Hormone Replacement Therapy Market Barriers Concerns about long-term HRT use, including increased risks of breast cancer, cardiovascular diseases, and stroke, limit patient adoption and regulatory approvals. The cost of HRT, especially newer formulations and customized therapies, can be a financial burden for patients, with limited insurance reimbursement restricting accessibility. To learn more about Hormone Replacement Therapy drivers and barriers, visit @ Hormone Replacement Therapy Competitive Landscape and Market Forecast Report Table of Contents 1. Hormone Replacement Therapy Market Report Introduction 2. Hormone Replacement Therapy Market Executive Summary 3. Competitive Landscape 4. Regulatory Analysis 5. Hormone Replacement Therapy Market Key Factors Analysis 6. Hormone Replacement Therapy Market Porter's Five Forces Analysis 7. Hormone Replacement Therapy Market Layout 8. Hormone Replacement Therapy Market Company and Product Profiles 9. KOL Views 10. Project Approach 11. About DelveInsight 12. Disclaimer & Contact Us About DelveInsight DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth. Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:


Cision Canada
39 minutes ago
- Cision Canada
AT&T Expands Nation's Largest Fiber Network, Now Reaching More Than 30 Million Fiber Locations
AT&T achieves key network expansion milestone ahead of schedule, solidifying U.S. fiber leadership by reaching even more Americans with world-class fiber internet. Key Takeaways: Fiber milestone underscores AT&T's connectivity leadership as America's largest and fastest-growing fiber broadband network and its commitment to delivering fast, reliable Internet connectivity backed by the AT&T Guarantee 1 Previously announced agreement to acquire substantially all of Lumen's Mass Markets fiber business supports goal of reaching approximately 60 million fiber locations by end of 2030 2 DALLAS, June 10, 2025 /CNW/ -- AT&T (NYSE:T) (the Company) has further cemented its position as the nation's leading fiber Internet provider by achieving its goal of passing more than 30 million consumer and business locations across the U.S. with its fiber broadband network ahead of plan. "We're proud to now pass more than 30 million fiber locations — halfway to our goal of reaching approximately 60 million homes and businesses across America," said John Stankey, chief executive officer of AT&T. "This accomplishment is a testament to our team's hard work over many years to build the nation's largest and fastest-growing fiber broadband network. Our investments in fiber are fueling economic growth and creating jobs, while delivering the fast, reliable connectivity Americans expect – backed by the AT&T Guarantee." As America's leading fiber provider, AT&T is focused on expanding where it can offer fiber in a variety of ways. This includes growing its organic in-region fiber network, its Gigapower joint venture, commercial open-access agreements, public-private partnerships and recently announced plans to acquire substantially all of Lumen's Mass Markets fiber business, which today includes about 1 million fiber customers and more than 4 million fiber locations across 11 states. Investment in America's Digital Future AT&T continues to put more fiber in the ground than anyone else and plans to accelerate network expansion efforts to meet increasing customer demand for the best broadband technology available today – fiber. As America's fastest internet with the most reliable speeds 3, AT&T Fiber is a critical enabler of economic opportunity, education, healthcare, and innovation. From 2020-2024, AT&T deployed thousands of miles of fiber optic infrastructure to connect communities and businesses nationwide and invested more than $145 billion primarily in its wireless and wireline networks, including capital investments and acquisitions of wireless spectrum. 4 AT&T continues to differentiate its fiber capabilities given its unique combination of network architecture expertise, size and scale, cost-effective growth path and an agile go-to-market approach. By reaching an industry-leading 30 million+ fiber locations passed, the Company is confident in its plans to reach approximately 60 million total fiber locations by the end of 2030. 2 The Company's fiber investments are also driving significant growth. Since the start of 2020, AT&T has passed millions of new fiber locations and added 5.7 million AT&T Fiber customers. Over the next five and a half years, AT&T expects to substantially grow its fiber customer base as it doubles where AT&T Fiber is available today. Committed to Putting Customers First AT&T remains focused on giving customers a premier connectivity experience. Backed by the AT&T Guarantee, AT&T Fiber is unmatched in its capabilities to help consumers and businesses of all sizes thrive in an increasingly digital economy, offering multi-gig speeds, built-in security, dependability, and optimal in-home coverage. AT&T is the first and only carrier to launch a customer guarantee for both its wireless and fiber networks and across both consumers and small businesses, reflecting AT&T's unwavering dedication to connecting customers at work, at home, and on the go. Additionally, by expanding its fiber network, AT&T is giving American consumers more choice when selecting broadband and wireless services the way they prefer – with fiber and 5G together. Customers with both AT&T Fiber and the Company's wireless services are more likely to recommend AT&T to others and remain customers longer. With award-winning fiber service and a customer-first approach, AT&T is shaping the future of connectivity. To check AT&T Fiber availability or sign up for updates, visit and To automatically receive AT&T financial news by email, please subscribe to email alerts. 1 Learn more at 2"Total locations" includes consumer and business locations (i) passed with fiber and (ii) served with fiber through commercial open-access providers. 3 Limited availability in select areas. Based on analysis by Ookla® of Speedtest Intelligence® data nationwide Speed Score and Consistency Score for Q3–Q4 2024. Ookla trademarks used under license and reprinted with permission. 4 The years ending December 31, 2020, through 2024 present results from continuing operations. About AT&T We help more than 100 million U.S. families, friends and neighbors, plus nearly 2.5 million businesses, connect to greater possibility. From the first phone call 140+ years ago to our 5G wireless and multi-gig internet offerings today, we @ATT innovate to improve lives. For more information about AT&T Inc. (NYSE:T), please visit us at Investors can learn more at

Montreal Gazette
an hour ago
- Montreal Gazette
‘A trophy asset': Developers are lining up to buy iconic downtown Bay building
Developers have already started bidding to purchase Montreal's iconic Hudson's Bay building on Ste-Catherine St. The new vocation for the 134-year-old building that helped launch Montreal's modern downtown core has yet to be determined, however. A little more than a month after it was announced the flagship store would be liquidated, one of 80 Hudson's Bay stores nationwide to be shut and sold because of faltering sales, interested buyers have put in bids, said Glenn Castanheira, director of the Montréal centre ville business development corporation. Who the bidders are and what their plans are for the building won't be known for another month or two, Castanheira said. Montréal centre-ville has been in regular contact with Hudson's Bay officials to discuss how to keep the site from becoming an urban eyesore until a new development project begins. 'We're happy, but we're not surprised there are multiple offers on the table, given how much of a trophy asset this building is,' Castanheira said. Located downtown across from the recently renovated Phillips Square, and with the reconstruction of Ste-Catherine St. in that sector completed, the area sees 90,000 people walking by on a good day. With its direct access to the métro system and proximity to a future REM light-rail station that will take passengers to Trudeau airport in 20 minutes, the building could be redeveloped in numerous ways, Castanheira said. Possibilities include a multi-storey residential development, a hotel or a mixed-use project with commercial spaces on the bottom floors and a condo tower or office buildings on top. 'On the ground floor you could imagine a mixed retail experience, with something like (gourmet Italian grocery store) Eataly,' he suggested. Or a hotel, with a lobby on the street level along with restaurants and specialized services like a spa and beauty salon. Brent Robinson, managing director for the Montreal branch of commercial real estate developer Cushman and Wakefield, also predicted The Bay building would be coveted. 'You're right on top of the métro, you're right on Ste-Catherine St. I'm not surprised to hear there's already some offers because the location alone is A class. I'm sure a lot of the major developers in the city are licking their chops over it.' Possible uses could include putting a large retailer on the lower floors, then residential or office space above. While vacancy rates for Class B and C office space is close to 20 per cent in Montreal's central core, according to Cushman and Wakefield's latest report, there is a lack of higher-quality Class A office space in downtown Montreal, Robinson said. There was a development proposal in 2021 to erect a 25-storey office tower on the north end of The Bay's building, which had the approval of city officials. Soaring vacancy rates caused by the COVID-19 pandemic scuttled that project. Lower interest rates and the levelling off of construction costs means 'the timing is better today for this project to hit the market than it would have been 18 months ago,' Robinson said. A challenge for any developer will be to maintain the heritage value of the distinctive red sandstone structure built in 1891. Two beaver pelts and one elk hide Major cities Canada-wide are grappling with how to repurpose their Bay stores. Winnipeg's six-storey Hudson's Bay closed in November 2020 after years of falling sales. Valued at $0 because of the predicted cost of renovations, The Bay handed over ownership in 2022 of the then 96-year-old building to an Indigenous organization in exchange for the symbolic payment of two beaver pelts and one elk hide. The Southern Chiefs Organization planned to spend $130 million to turn it into a mixed-use building that would include affordable housing for First Nations people, restaurants and a museum. The Ste-Catherine St. store is evaluated at $64,130,000, according to Montreal's property assessment roll. Hudson's Bay paid $2.2 million in taxes on the 564,000-square-foot property in 2024. British Columbia billionaire real estate developer Weihong (Ruby) Liu signed an agreement to purchase the leases for 28 Bay stores across Canada to create her own retail chain. She chose suburban sites that she said would be easier to redevelop than flagship stores. Converting the Montreal property could take as long as 10 years, Castanheira said. Local merchants are worried the building could fall into disrepair, becoming a magnet for graffiti, drug use, squatters or worse. Many of Montreal's vacant sites have been the victims of arson. They include the three-storey building next to the Super Sexe strip bar across the street from the Eaton Centre, which burnt down in 2021. The lot where it once stood is still a vacant hole on Ste-Catherine St. in the heart of the downtown core. 'Montreal has some very lax bylaws when it comes to managing vacant properties,' Castanheira said. His main worry is the property will be bought by a building speculator who lets it sit vacant for decades. Another concern is that Montreal, which has ultimate say over zoning laws, could take a long time to issue the necessary permits to allow redevelopment, said Concordia University economist Moshe Lander. 'Whether you're putting in residential space or commercial or industrial space, it's often the municipalities that become the impediment, saying we need to review,' Lander said. 'That's partly why Canada as a whole finds itself in a major housing crisis. And Montreal happens to be particularly bad.' Montréal centre-ville is in talks with the Hudson's Bay Company to maintain the facade and dress up the windows of the hulking edifice with images showing the history of the building. With other large downtown retail sites possibly facing the same fate as The Bay, Montreal needs to develop an urban plan to prepare for their departures, Lander said. 'The Bay is one of many changes that are going to happen over the next 10 to 20 years,' he said. 'Is there a plan in place? Is there a vision, or are we going to keep doing this in a piecemeal sort of way?' History of The Bay building Scottish-born retail magnate Henry Morgan made the risky decision to move his flourishing business from Victoria Square in lower Montreal to the mainly residential area on Ste-Catherine St. W. in 1891. Morgan was betting urban development would move further north and was proven right, with his store selling dry goods, dresses and fashion items paving the way for the development of Montreal's modern downtown core. Morgan spared little expense, importing high-quality red sandstone for the facade of the four-storey building. He hired Scottish architect John Pierce, who designed the department store in the grand Richardsonian Romanesque style, characterized by heavy stonework, rounded arches and deeply recessed openings. The building was considered to be 'the finest structure devoted to the retail business in North America,' historian Robert N. Wilkins wrote in The Gazette in 2014. The store, run by Morgan's family after his death in 1893, was prosperous. In 1923, it expanded northward with the construction of an eight-storey structure. There was a Steinberg's grocery store in the basement starting in 1952. In 1960, the Hudson's Bay Company bought Morgan's and enlarged the store again, moving it all the way to de Maisonneuve Blvd. by 1967. It was still known as Morgan's till 1972. The Hudson's Bay Company announced in April it would be liquidating all of its 80 stores across Canada.